Initially, leptin is thought to have anti-steatotic effects, but with the progression of MASLD, leptin develops proinflammatory and fibrogenic properties and may enhance disease progression and associated complications [34]. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.